Telangana’s Drugs Control Administration has advised the public to avoid using oral formulations containing Nimesulide above 100 milligrams in immediate release form, following a directive from the Union Ministry of Health and Family Welfare. Nimesulide, a non-steroidal anti-inflammatory drug, is known for potential liver toxicity and other adverse effects. Patients using such medications are urged to discontinue them and seek advice from a Registered Medical Practitioner for safer alternatives.
The Drugs Control Administration emphasized the importance of not purchasing, using, or storing these prohibited formulations due to potential health risks. Steps are being taken to remove these products from the market and supply chain in Telangana. The public is requested to report any instances of sale or distribution of these banned formulations to the nearest Drugs Inspector or Drugs Control Administration office.
The ban on high-dose Nimesulide products for human use, under Section 26A of the Drugs and Cosmetics Act, 1940, aims to enhance safety standards and eliminate high-risk medicines. Pharmaceutical companies selling Nimesulide brands are required to stop production and recall affected batches. Lower dose formulations and alternative therapies remain unaffected by the prohibition.
